Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Angiogenesis
Erschienen in: Angiogenesis 2/2010

01.06.2010 | Original Paper

Molecular ultrasound assessment of tumor angiogenesis

verfasst von: Nirupama Deshpande, Marybeth A. Pysz, Jürgen K. Willmann

Erschienen in: Angiogenesis | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Angiogenesis, the growth of new blood vessels, plays a critical role in progression of tumor growth and metastasis, making it an attractive target for both cancer imaging and therapy. Several molecular markers, including those that are involved in the angiogenesis signaling pathway and those unique to tumor angiogenic vessels, have been identified and can be used as targets for molecular imaging of cancer. With the introduction of ultrasound contrast agents that can be targeted to those molecular markers, targeted contrast-enhanced ultrasound (molecular ultrasound) imaging has become an attractive imaging modality to non-invasively assess tumor angiogenesis at the molecular level. The advantages of molecular ultrasound imaging such as high temporal and spatial resolution, non-invasiveness, real-time imaging, relatively low cost, lack of ionizing irradiation and wide availability among the imaging community will further expand its roles in cancer imaging and drug development both in preclinical research and future clinical applications.
Literatur
1.
Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410CrossRefPubMed
2.
3.
4.
Algire GH, Chalkley HW, Legallais FY, Park HD (1945) Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 6:73–85
5.
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31CrossRefPubMed
6.
7.
8.
Abdelrahim M, Konduri S, Basha R, Philip PA, Baker CH (2010) Angiogenesis: an update and potential drug approaches (review). Int J Oncol 36:5–18PubMed
9.
Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027CrossRefPubMed
10.
Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571CrossRefPubMed
11.
Bernabeu C, Lopez-Novoa JM, Quintanilla M (2009) The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 1792:954–973PubMed
12.
Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29:10–14PubMed
13.
Ferrara N (2005) The role of VEGFR in the regulation of physiological and pathological angiogenesis. In: Clauss M, Breier G (eds) Mechanisms of angiogenesis. Birkhaeuser Basel Press, Switzerland, pp 209–231CrossRef
14.
Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611CrossRefPubMed
15.
Brekken RA, Thorpe PE (2001) VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release 74:173–181CrossRefPubMed
16.
Paz K, Zhu Z (2005) Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Front Biosci 10:1415–1439CrossRefPubMed
17.
Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9–22CrossRefPubMed
18.
Cai W, Chen X (2006) Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 6:407–428CrossRefPubMed
19.
Stollman TH, Ruers TJ, Oyen WJ, Boerman OC (2009) New targeted probes for radioimaging of angiogenesis. Methods 48:188–192CrossRefPubMed
20.
Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J et al (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 59:612–618CrossRefPubMed
21.
Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S et al (1999) Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 154:1345–1352PubMed
22.
Silacci M, Brack SS, Spath N, Buck A, Hillinger S et al (2006) Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 19:471–478CrossRefPubMed
23.
Fonsatti E, Altomonte M, Arslan P, Maio M (2003) Endoglin (CD105): a target for anti-angiogenetic cancer therapy. Curr Drug Targets 4:291–296CrossRefPubMed
24.
Ma X, Labinaz M, Goldstein J, Miller H, Keon WJ et al (2000) Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol 20:2546–2552PubMed
25.
Kolonin MG (2009) Tissue-specific targeting based on markers expressed outside endothelial cells. Adv Genet 67:61–102CrossRefPubMed
26.
Hardwick JS, Yang Y, Zhang C, Shi B, McFall R et al (2005) Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. Mol Cancer Ther 4:413–425PubMed
27.
Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD et al (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681PubMed
28.
Conway RE, Petrovic N, Li Z, Heston W, Wu D et al (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26:5310–5324CrossRefPubMed
29.
Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R (2002) Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 79:547–552CrossRefPubMed
30.
Seth P, Lin Y, Hanai J, Shivalingappa V, Duyao MP et al (2005) Magic roundabout, a tumor endothelial marker: expression and signaling. Biochem Biophys Res Commun 332:533–541CrossRefPubMed
31.
Sheldon H, Andre M, Legg JA, Heal P, Herbert JM et al (2009) Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors. FASEB J 23:513–522CrossRefPubMed
32.
Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M et al (2006) Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 6:144CrossRefPubMed
33.
Chen J, Zhuang G, Frieden L, Debinski W (2008) Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res 68:10031–10033CrossRefPubMed
34.
Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM (2006) The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol 102:15–21CrossRefPubMed
35.
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545CrossRefPubMed
36.
Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P et al (2009) Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214:761–777CrossRefPubMed
37.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081CrossRefPubMed
38.
Mankoff DA (2007) A definition of molecular imaging. J Nucl Med 48:18N 21NPubMed
39.
Peterson TE, Manning HC (2009) Molecular imaging: 18F-FDG PET and a whole lot more. J Nucl Med Technol 37:151–161CrossRefPubMed
40.
Burtscher IM, Holtas S (2001) Proton MR spectroscopy in clinical routine. J Magn Reson Imaging 13:560–567CrossRefPubMed
41.
42.
Krafft C, Steiner G, Beleites C, Salzer R (2009) Disease recognition by infrared and Raman spectroscopy. J Biophotonics 2:13–28CrossRefPubMed
43.
Sahu RK, Mordechai S (2005) Fourier transform infrared spectroscopy in cancer detection. Future Oncol 1:635–647CrossRefPubMed
44.
Ellis DI, Dunn WB, Griffin JL, Allwood JW, Goodacre R (2007) Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 8:1243–1266CrossRefPubMed
45.
Pysz M, Gambhir SS, Willmann JK (2010) Molecular Imaging: current status and emerging strategies. Clin Radiol 65:500–515CrossRefPubMed
46.
Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C et al (2009) Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 11:861–870CrossRefPubMed
47.
Dijkgraaf I, Boerman OC (2009) Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm 24:637–647CrossRefPubMed
48.
Willmann JK, Cheng Z, Davis C, Lutz AM, Schipper ML et al (2008) Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 249:212–219CrossRefPubMed
49.
Contag CH (2007) In vivo pathology: seeing with molecular specificity and cellular resolution in the living body. Annu Rev Pathol 2:277–305CrossRefPubMed
50.
Wang TD, Friedland S, Sahbaie P, Soetikno R, Hsiung PL et al (2007) Functional imaging of colonic mucosa with a fibered confocal microscope for real-time in vivo pathology. Clin Gastroenterol Hepatol 5:1300–1305CrossRefPubMed
51.
Kim HL (2009) Optical imaging in oncology. Urol Oncol 27:298–300PubMed
52.
Ritchie WA, Thompson W (1979) A clinical assessment of real time ultrasound. Ir J Med Sci 148:251–254CrossRefPubMed
53.
Deshpande N, Needles A, Willmann JK (2010) Molecular ultrasound imaging: current status and future directions. Clin Radiol 65:567–581CrossRefPubMed
54.
Wilson SR, Jang HJ, Kim TK, Iijima H, Kamiyama N et al (2008) Real-time temporal maximum-intensity-projection imaging of hepatic lesions with contrast-enhanced sonography. AJR Am J Roentgenol 190:691–695CrossRefPubMed
55.
Celli N, Gaiani S, Piscaglia F, Zironi G, Camaggi V et al (2007) Characterization of liver lesions by real-time contrast-enhanced ultrasonography. Eur J Gastroenterol Hepatol 19:3–14CrossRefPubMed
56.
Weskott HP (2008) Emerging roles for contrast-enhanced ultrasound. Clin Hemorheol Microcirc 40:51–71PubMed
57.
Perkins AC, Frier M, Hindle AJ, Blackshaw PE, Bailey SE et al (1997) Human biodistribution of an ultrasound contrast agent (Quantison) by radiolabelling and gamma scintigraphy. Br J Radiol 70:603–611PubMed
58.
Klibanov AL (2009) Preparation of targeted microbubbles: ultrasound contrast agents for molecular imaging. Med Biol Eng Comput 47:875–882CrossRefPubMed
59.
Klibanov AL, Hughes MS, Villanueva FS, Jankowski RJ, Wagner WR et al (1999) Targeting and ultrasound imaging of microbubble-based contrast agents. MAGMA 8:177–184CrossRefPubMed
60.
Klibanov AL (2005) Ligand-carrying gas-filled microbubbles: ultrasound contrast agents for targeted molecular imaging. Bioconjug Chem 16:9–17CrossRefPubMed
61.
Pochon S, Tardy I, Bussat P, Bettinger T, Brochot J et al (2010) BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol 45:89–95CrossRefPubMed
62.
Pysz MA, Foygel K, Rosenberg J, Gambhir SS, Schneider M et al. (2010) Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology. doi:10.​1148/​radiol.​10091858
63.
Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR et al (2010) Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 51:433–440CrossRefPubMed
64.
Kimura RH, Cheng Z, Gambhir SS, Cochran JR (2009) Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 69:2435–2442CrossRefPubMed
65.
Kimura RH, Levin AM, Cochran FV, Cochran JR (2009) Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins 77:359–369CrossRefPubMed
66.
Jun HY, Park SH, Kim HS, Yoon KH (2010) Long residence time of ultrasound microbubbles targeted to integrin in murine tumor model. Acad Radiol 17:54–60CrossRefPubMed
67.
Willmann JK, Lutz AM, Paulmurugan R, Patel MR, Chu P et al (2008) Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 248:936–944CrossRefPubMed
68.
Pillai R, Marinelli ER, Swenson RE (2006) A flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups. Biopolymers 84:576–585CrossRefPubMed
69.
Pillai R, Marinelli ER, Fan H, Nanjappan P, Song B et al (2010) A phospholipid-PEG2000 conjugate of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeting heterodimer peptide for contrast-enhanced ultrasound imaging of angiogenesis. Bioconjug Chem 21:556–562CrossRef
70.
Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA (2007) Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 13:323–330CrossRefPubMed
71.
Marshall D, Pedley RB, Boden JA, Boden R, Melton RG et al (1996) Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br J Cancer 73:565–572PubMed
72.
Cai W, Chen X (2008) Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 49(Suppl 2):113S–128SCrossRefPubMed
73.
Cai W, Gambhir SS, Chen X (2008) Chapter 7. Molecular imaging of tumor vasculature. Methods Enzymol 445:141–176CrossRefPubMed
74.
Miao Z, Ren G, Liu H, Kimura RH, Jiang L et al (2009) An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem 20:2342–2347CrossRefPubMed
75.
Hu G, Lijowski M, Zhang H, Partlow KC, Caruthers SD et al (2007) Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles. Int J Cancer 120:1951–1957CrossRefPubMed
76.
Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B et al (2007) Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 67:1555–1562CrossRefPubMed
77.
Ellegala DB, Leong-Poi H, Carpenter JE, Klibanov AL, Kaul S et al (2003) Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 108:336–341CrossRefPubMed
78.
Zavaleta C, de la Zerda A, Liu Z, Keren S, Cheng Z et al (2008) Noninvasive Raman spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes. Nano Lett 8:2800–2805CrossRefPubMed
79.
Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S et al (2002) The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62:5912–5919PubMed
80.
Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K et al (2007) Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 13:504–509CrossRefPubMed
81.
Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR et al (2007) In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48:1313–1319CrossRefPubMed
82.
Willmann JK, Paulmurugan R, Chen K, Gheysens O, Rodriguez-Porcel M et al (2008) US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 246:508–518CrossRefPubMed
83.
Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BT et al (2005) Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 4:1423–1429CrossRefPubMed
84.
Chen K, Li ZB, Wang H, Cai W, Chen X (2008) Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 35:2235–2244CrossRefPubMed
85.
Lee DJ, Lyshchik A, Huamani J, Hallahan DE, Fleischer AC (2008) Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med 27:855–866PubMed
86.
Rychak JJ, Graba J, Cheung AM, Mystry BS, Lindner JR et al (2007) Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Mol Imaging 6:289–296PubMed
87.
Lyshchik A, Fleischer AC, Huamani J, Hallahan DE, Brissova M et al (2007) Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med 26:1575–1586PubMed
88.
Weller GE, Wong MK, Modzelewski RA, Lu E, Klibanov AL et al (2005) Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res 65:533–539PubMed
89.
Palmowski M, Huppert J, Ladewig G, Hauff P, Reinhardt M et al (2008) Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther 7:101–109CrossRefPubMed
90.
91.
Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS (2008) Molecular imaging in drug development. Nat Rev Drug Discov 7:591–607CrossRefPubMed
92.
Nune SK, Gunda P, Thallapally PK, Lin YY, Forrest ML et al (2009) Nanoparticles for biomedical imaging. Expert Opin Drug Deliv 6:1175–1194CrossRefPubMed
93.
Blanco E, Kessinger CW, Sumer BD, Gao J (2009) Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) 234:123–131CrossRef
94.
Sosnovik DE, Weissleder R (2007) Emerging concepts in molecular MRI. Curr Opin Biotechnol 18:4–10CrossRefPubMed
95.
Bentolila LA, Ebenstein Y, Weiss S (2009) Quantum dots for in vivo small-animal imaging. J Nucl Med 50:493–496CrossRefPubMed
96.
Wang H, Cai W, Chen K, Li ZB, Kashefi A et al (2007) A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 34:2001–2010CrossRefPubMed
97.
Barrett T, Choyke PL (2008) Imaging angiogenesis. In: Figg W, Folkman J (eds) Angiogenesis: an integrative approach from science to medicine. Springer Press, US, pp 321–331
Metadaten
Titel
Molecular ultrasound assessment of tumor angiogenesis
verfasst von
Nirupama Deshpande
Marybeth A. Pysz
Jürgen K. Willmann
Publikationsdatum
01.06.2010
Verlag
Springer Netherlands
Erschienen in
Angiogenesis / Ausgabe 2/2010
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-010-9175-z

Weitere Artikel der Ausgabe 2/2010

Angiogenesis 2/2010 Zur Ausgabe

OriginalPaper

Non-invasive imaging of angiogenesis in head and neck squamous cell carcinoma

Original Paper

Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of atherosclerotic plaque angiogenesis

Original Paper

Magnetic resonance imaging of brain angiogenesis after stroke

OriginalPaper

Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions

Editorial Note

Imaging of angiogenesis

Original Paper

Visualizing vascular permeability and lymphatic drainage using labeled serum albumin

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise